brentuximab vedotin

Ligand id: 6772

Name: brentuximab vedotin

1. Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER. (1993)
Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation.
J. Immunol.151 (11): 5896-906. [PMID:8245437]
2. FDA. 
FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma.
Accessed on 10/11/2017. Modified on 10/11/2017.,
3. Francisco JA, Risdon G, Wahl AF, Siegall C. (2006)
immunotherapy; fusion proteins; antitumor agents; for treatment and prevention of hodgkin's disease.
Patent number: US7090843. Assignee: Seattle Genetics, Inc. Priority date: 09/12/2014. Publication date: 15/08/2006.
4. Mitra A, Sept D. (2004)
Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
Biochemistry43 (44): 13955-62. [PMID:15518544]
5. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A et al.. (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet,  [Epub ahead of print]. [PMID:25796459]